Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNTA OTCMKTS:HPPI NASDAQ:SLGL OTC:ZOMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$3.44$3.69$2.74▼$7.28$62.92M0.628,228 shs2,140 shsHPPIHedgePath Pharmaceuticals$0.05-1.2%$0.05$0.04▼$0.32$32.16M-1.1619,283 shs100 shsSLGLSol-Gel Technologies$25.93-5.9%$15.03$4.01▼$30.00$76.75M1.2632,754 shs9,185 shsZOMDFZomedica$0.09+11.1%$0.04$0.02▼$0.16$88.20M1.823.88 million shs4.35 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science-1.43%-4.58%-8.14%-9.95%-16.10%HPPIHedgePath Pharmaceuticals-1.25%+10.91%+19.51%+6.52%-28.96%SLGLSol-Gel Technologies-5.88%+10.91%+62.16%+274.71%+347.07%ZOMDFZomedica+11.11%+100.00%+140.64%+109.30%-30.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$3.44$3.69$2.74▼$7.28$62.92M0.628,228 shs2,140 shsHPPIHedgePath Pharmaceuticals$0.05-1.2%$0.05$0.04▼$0.32$32.16M-1.1619,283 shs100 shsSLGLSol-Gel Technologies$25.93-5.9%$15.03$4.01▼$30.00$76.75M1.2632,754 shs9,185 shsZOMDFZomedica$0.09+11.1%$0.04$0.02▼$0.16$88.20M1.823.88 million shs4.35 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science-1.43%-4.58%-8.14%-9.95%-16.10%HPPIHedgePath Pharmaceuticals-1.25%+10.91%+19.51%+6.52%-28.96%SLGLSol-Gel Technologies-5.88%+10.91%+62.16%+274.71%+347.07%ZOMDFZomedica+11.11%+100.00%+140.64%+109.30%-30.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNTAGenenta Science 3.00Buy$25.00626.74% UpsideHPPIHedgePath Pharmaceuticals 0.00N/AN/AN/ASLGLSol-Gel Technologies 0.00N/AN/AN/AZOMDFZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/A($0.01) per shareN/ASLGLSol-Gel Technologies$11.54M6.27N/AN/A$10.36 per share2.50ZOMDFZomedicaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AHPPIHedgePath Pharmaceuticals-$4.55MN/A0.00∞N/AN/AN/A-246.03%N/ASLGLSol-Gel Technologies-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)ZOMDFZomedicaN/A-$0.10N/A∞N/AN/AN/AN/AN/ALatest HPPI, GNTA, SLGL, and ZOMDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025SLGLSol-Gel Technologies-$0.67$4.17+$4.84$4.17$2.86 million$17.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNTAGenenta ScienceN/AN/AN/AN/AN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/AZOMDFZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNTAGenenta ScienceN/A6.896.89HPPIHedgePath PharmaceuticalsN/A6.766.76SLGLSol-Gel TechnologiesN/A7.327.32ZOMDFZomedicaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNTAGenenta Science15.13%HPPIHedgePath PharmaceuticalsN/ASLGLSol-Gel Technologies26.18%ZOMDFZomedica8.95%Insider OwnershipCompanyInsider OwnershipGNTAGenenta Science28.99%HPPIHedgePath Pharmaceuticals4.80%SLGLSol-Gel Technologies66.51%ZOMDFZomedica5.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableHPPIHedgePath Pharmaceuticals1370.45 millionN/ANot OptionableSLGLSol-Gel Technologies502.79 million933,000OptionableZOMDFZomedica50979.95 millionN/AN/AHPPI, GNTA, SLGL, and ZOMDF HeadlinesRecent News About These CompaniesZomedica strengthens UK market position with strategic distribution agreement with Pioneer Veterinary Products for high-growth veterinary innovation portfolioSeptember 4, 2025 | pharmabiz.comPZomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation PortfolioSeptember 3, 2025 | accessnewswire.comAZomedica Corporation and VerticalVet partner to deliver advanced veterinary technologies to independent practicesAugust 22, 2025 | pharmabiz.comPZomedica Corp. Reports Q2 2025 Financial ResultsAugust 22, 2025 | msn.comZomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent PracticesAugust 19, 2025 | accessnewswire.comAZomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary MedicineAugust 12, 2025 | accessnewswire.comAZomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support GrowthAugust 6, 2025 | accessnewswire.comAZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | financialpost.comFZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | globenewswire.comZomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for PetsJuly 16, 2025 | accessnewswire.comAZomedica Announces Strategic PulseVet(R) Shock Wave Partnership with World Equestrian Center – OcalaJuly 10, 2025 | accessnewswire.comAZomedica Announces Issuance of Additional Patent for its TRUVIEW(R) MicroscopeJune 24, 2025 | accessnewswire.comAZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | finanznachrichten.deZomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | accessnewswire.comAZomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample DilutionMay 21, 2025 | accessnewswire.comAZomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 19, 2025 | accessnewswire.comAZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comZomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support GrowthMay 15, 2025 | accessnewswire.comAZomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave TherapyMay 13, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeHPPI, GNTA, SLGL, and ZOMDF Company DescriptionsGenenta Science NASDAQ:GNTA$3.40 -0.04 (-1.31%) As of 09/9/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.HedgePath Pharmaceuticals OTCMKTS:HPPI$0.05 0.00 (-1.21%) As of 09/8/2025HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.Sol-Gel Technologies NASDAQ:SLGL$25.93 -1.62 (-5.88%) Closing price 09/9/2025 03:59 PM EasternExtended Trading$25.92 -0.01 (-0.04%) As of 09/9/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Zomedica OTC:ZOMDF$0.09 +0.01 (+11.11%) As of 09/9/2025 03:59 PM EasternZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
